TRIal For Efficacy of Capre on hyperTriglyceridemiA

Exclusion Criteria

• •Any concomitant medication which in the opinion of the investigator would preclude the patient from successfully participating in the study.
• •Women who are pregnant or that are breast feeding.
• •Participation in another clinical trial within 30 days from initiation of the study.
• •Participants with a high risk for cardiovascular disease; (The definition of high-risk individuals will follow that of the 2009 Canadian Guidelines and include a) FRS \>= 20% 10-year risk; b) All patients with uncontrolled diabetes (DCA guidelines) and c) Evidence of atherosclerosis -when this evidence was ascertained when clinically indicated);
• •Systolic blood pressure \>140 mmHg and/or diastolic blood pressure \>90 mmHg. In diabetic patients, systolic blood pressure \> 130 mmHg and/or diastolic blood pressure \> 90 mmHg.
• •History of stroke, intermittent claudication or transient ischemic attack.
• •Known unstable (uncontrolled) cardiac disease , within the last 6 months.
• •Patient with a clinically significant abnormal ECG at screening.
• •Patients with uncontrolled diabetes mellitus, with HbA1c \> 7.0%.
• •Known diagnosis of hypoglycemia.
• •Evidence of active renal disease indicated by a fasting estimated glomerular filtration rate (eGFR) of \< 60 ml/min per 1.73 m2.
• •Increased plasma levels (\>ULN) of amylase (as per respective lab upper limits) and / or lipase (\>160 IU/L) or any indication of pancreatitis pancreatitis (increased alcohol consumption, gallstones).
• •History of pancreatitis.
• •Use of any lipid lowering medication other than statins or ezetimibe(e.g niacin, fibrates) and/or lipid lowering NHP within 6 weeks prior to the screening visit.
• •Intake of \> 2 servings per week of fish or regimented use of fish oil/omega-3 supplements within 6 weeks prior to the screening visit.
• •Known HIV or Hepatitis B or C positive.
• •Patients with uncontrolled asthma as defined by the 2010 Consensus Summary of the Canadian Thoracic Society.
• •Known seafood allergy or allergy to any of the medicinal or non-medicinal ingredients of the study medication and placebo, including:
• •1. Omega-3 fatty acids (including EPA and DHA)
• •2. Phospholipids (mainly phosphatidylcholine)
• •3. Astaxanthin
• •4. Microcrystalline cellulose
• •Coagulopathy or on anticoagulants. Platelet aggregation inhibitors (such as aspirin or clopidogrel but not heparin) are permitted in the study; patients taking both aspirin and clopidogrel are not permitted in the study.
• •Unable or unwilling to comply with the protocol.
• •Patient reported weight was not stable for the past 6 months (within 3kg variation).
• •Consumption of more than 14 standard alcoholic drinks a week.